- First: the Oxford University vaccine proved safe and effective in the first clinical trial
- Second: T-cells with antibodies were also developed in the trial of the vaccine of the Chinese army and pharma company, Cancino.
- Third: Germany’s BioNotech firm in collaboration with US drug company Pfizer to develop vaccine, increasing T-sales response to a large extent
The results of the corona vaccine trial at Oxford University were released on Monday. Expectations from two more large vaccines have increased after the trial yielded better results. The results of their initial trials have also been in line with expectations. The first vaccine is from Chinese pharma company Cancino Biologics, whose next phase of trials are underway. Cancino is trying to produce the world’s first vaccine, overtaking Western Pharma. The third vaccine is from German company BioNotech.
Also Read: Rajasthan’s bet in terms of statistics, ‘loyalty’ is necessary for CM Gehlot
Status of Trial of Three Big Vaccines
First: Oxford University’s vaccine proved to be safe and effective
The first clinical trial of the Coronavirus vaccine at Oxford University has yielded good results. According to a report published in the medical journal The Lancet on Monday, the vaccine is completely safe and effective. After this information, the Oxford vaccine has come forward in the list of frontrunner vaccines.
The tweet from Oxford University also said that applying this vaccine named AZD1222 has given good immune response. The team involved in the vaccine trial and the Oxford Monitoring Group did not see any concern about safety in this vaccine and this has led to a strong response.
Second: Two trials of Chinese company Cancino complete, results found as expected.
Cancino Biologics is one of the companies in the world that presented the full results of the first trial in May. The company was in the news due to the speed in human trials. The company has completed two out of three trials. The third phase trial is going on. The vaccine, named Ad5-nCOV, has been developed by the company in collaboration with the Army of China. Researchers reported on Monday that the cancer vaccine has been tested on 508 people. During testing people have developed immunity in their body. This is to be tested on a larger scale in the next phase. This vaccine developed antibodies in the body as well as T-cells.
The third phase of another vaccine trial has begun in China. This vaccine is manufactured by Chinese company Sinopharm CNBG. The clinical trial of this vaccine was initiated by Sheikh Abdullah bin Mohammed Al Hamad of the UAE after registration with the WHO. The UAE has people from around 200 countries, so vaccine trials are allowed here. According to UAE officials, 15 volunteers are participating in this trial.
Third: The German company BioNotech’s vaccine trial proved to be safe. The
third important vaccine is being manufactured by the German biotech firm American drug company Pfizer. The vaccine trial was conducted on 60 healthy people. As a result, the vaccine is safe and the immune response was better in volunteers. In another trial in America, the same result was revealed.
The company says the trial data showed that it increased the response to large-scale T-cells to eliminate coronaviruses. These T-cells eliminate the virus’s ability to spread infection. Experts say that it will take 12–18 months to prepare a safer and better vaccine.
